First Long Island Investors LLC Has $56.62 Million Position in Abbott Laboratories $ABT

First Long Island Investors LLC trimmed its position in Abbott Laboratories (NYSE:ABT) by 1.4% in the first quarter, according to its most recent filing with the SEC. The fund owned 426,824 shares of the healthcare product maker’s stock after selling 6,080 shares during the period. Abbott Laboratories accounts for approximately 4.7% of First Long Island Investors LLC’s investment portfolio, making the stock its 3rd biggest position. First Long Island Investors LLC’s holdings in Abbott Laboratories were worth $56,618,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of ABT. Hughes Financial Services LLC acquired a new position in Abbott Laboratories in the 1st quarter valued at approximately $27,000. Abound Financial LLC acquired a new position in Abbott Laboratories in the 1st quarter valued at approximately $28,000. Elequin Capital LP acquired a new position in Abbott Laboratories in the 1st quarter valued at approximately $30,000. Wormser Freres Gestion acquired a new position in Abbott Laboratories in the 4th quarter valued at approximately $32,000. Finally, JCIC Asset Management Inc. acquired a new position in Abbott Laboratories in the 1st quarter valued at approximately $32,000. 75.18% of the stock is currently owned by institutional investors.

Abbott Laboratories Stock Performance

Shares of Abbott Laboratories stock opened at $132.56 on Friday. The company has a current ratio of 1.82, a quick ratio of 1.30 and a debt-to-equity ratio of 0.25. The business has a 50-day moving average price of $130.40 and a two-hundred day moving average price of $131.33. Abbott Laboratories has a 1-year low of $110.86 and a 1-year high of $141.23. The company has a market cap of $230.72 billion, a P/E ratio of 16.61, a PEG ratio of 2.45 and a beta of 0.69.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.26. The firm had revenue of $11.14 billion during the quarter, compared to the consensus estimate of $11.01 billion. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The business’s revenue was up 7.4% compared to the same quarter last year. During the same period last year, the business posted $1.14 EPS. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. As a group, analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on ABT shares. Morgan Stanley upped their price target on shares of Abbott Laboratories from $127.00 to $137.00 and gave the company an “equal weight” rating in a research report on Tuesday, July 15th. Leerink Partners started coverage on shares of Abbott Laboratories in a research report on Monday, June 16th. They issued a “market perform” rating and a $143.00 price target for the company. Raymond James Financial decreased their price target on shares of Abbott Laboratories from $142.00 to $141.00 and set an “outperform” rating for the company in a research report on Friday, July 18th. Mizuho increased their price objective on shares of Abbott Laboratories from $130.00 to $140.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 16th. Finally, Royal Bank Of Canada increased their price objective on shares of Abbott Laboratories from $145.00 to $147.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 15th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Abbott Laboratories currently has an average rating of “Moderate Buy” and a consensus price target of $144.47.

Insider Buying and Selling

In other Abbott Laboratories news, CFO Philip P. Boudreau sold 5,550 shares of the firm’s stock in a transaction on Friday, August 8th. The shares were sold at an average price of $134.55, for a total value of $746,752.50. Following the completion of the sale, the chief financial officer directly owned 51,003 shares in the company, valued at approximately $6,862,453.65. This trade represents a 9.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.46% of the company’s stock.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.